Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of subcutaneous ianalumab in moderate to severe primary Sjogren's syndrome
2016-003292-22Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ianalumab in Sjögren's syndrome (SS) (4 arms), sponsored by Novartis. Primary endpoint: Primary dose-response in physician-assessed multidimensional disease activity at 24 weeks. Started Mar 2017; status: completed.
02
Drugs
ianalumab
03
Conditions
Sjögren's syndrome (SS)
Beyond the preview
Go deeper on 2016-003292-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003292-22.